|
|
 |
|
Viewing report
|
|
|
|
Drug Delivery Technology - Revolutionizing Cancer Therapies
PharmaVision, April 2007, Pages: 80
'One of the biggest issues with current cancer therapies is that whilst most therapies procure quality of life they kill both healthy and tumor cells. This offers drug delivery specialists a challenge and opportunity to increase the therapeutic index and ultimately deliver targeted therapies to cancer cells whilst minimizing off-target side effects.” Dr Cheryl Barton.
Whilst significant advances have been made in the treatment of many cancer subtypes, the therapies currently available often require regular visits to the hospital or clinic to receive radioactive therapy or intravenous chemotherapy which are highly toxic, may lead to drug resistance and are poorly tolerated due to limited-tumor specificity leading to many unwanted side-effects and poor compliance.
While the pharmaceutical industry continues to find innovative ways to treat cancer, drug delivery specialists have the task of making sure those treatments reach the correct site in the body in the required quantities and at the right time. The Holy Grail in delivering cancer therapies is the development of a technology platform which targets the therapy only to the tumor, leaving normal cells undamaged. In an ideal world, orally active targeted therapies would be available.
The following report summarizes the latest developments in cancer drug development and analyzes some of the most promising solutions which drug delivery companies are providing in order to address this unmet clinical need.
-Gain an in-depth understanding of the technology landscape for active & passive targeting platforms, including injectable & oral systems
-Assess the options available for delivering anticancer compounds now & in the future
-Gauge the current & future technology requirements of pharma & biotech companies developing oncology products
-Analyze how the market is evolving & the influence that drug delivery may have on pharma oncology pipelines
-Identify key pharma & delivery companies focusing on the improved delivery of existing & novel anticancer agents
-Highlight alliances between delivery companies & pharma, and recent market activity
-Evaluate where progress has been made in the delivery of potential new oncology products
Eight Questions This Note Answers:
1. How will the drug delivery technology drivers change in the cancer arena in the next decade and beyond?
2. What are the key delivery technologies in the oncology field?
3. When are products which utilise these key delivery technologies likely to reach the market?
5. Which companies are the winners in each technology category?
6. How are drug delivery technologies evolving to meet the demands of the oncology market?
7. Where are the market opportunities now and in the future?
8. What do we predict will be the value of the cancer drug delivery market each year until 2012, in 2015 and in 2020?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Nanoparticle Drug Delivery Market Report
Targeted Drug Delivery Technologies: Players, products & prospects to 2015
Drug Delivery Technology - Revolutionizing CNS Therapies
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Drug Delivery Technology - Revolutionizing Cardiovascular Treatment
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Drug Delivery Systems in Cancer Therapeutics
Transdermal Drug Delivery - Technologies, Markets, and Companies
Drug Delivery Technologies - Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies
Next Generation Protein Engineering and Drug Design: Strategies to boost efficacy and improve drug delivery
Drug Delivery: Active Transdermal Delivery Systems
|
|
|
|
